Michael Morrison:
Dickenson's greatest achievement in this book is that she largely succeeds in creating a coherent, compelling narrative across the five disparate case studies and that she does so incorporating insights from a range of domains including sociology, ethics, philosophy, law and biomedicine.
This book is filled with clearly explained, hard science, giving equal treatment to the benefits and problems of personalized medicine.... I recommend expending the necessary reading effort not only for healthcare workers but for the general public.
Dickenson's mapping out of this vital fork in the road is valuable.
Marcy Darnovsky, executive director, Center for Genetics and Society:
If you are wondering what to make of personalized medicine's grand claims, let Dickenson be your guide. Turning her keen scientific and political intelligence to biotech visions of individually tailored drugs, consumer gene tests, enhancement technologies, and more, she finds tidbits of hope for improving health care among scads of hype—some of it dangerous. This must-read book makes a powerful case for taming market domination and 'me-centeredness' and for renewing our commitments to public health and the common good.
Michele B. Goodwin, University of Minnesota, and editor of Baby Markets: Money and the New Politics of Creating Families:
Recognizing that there are trade-offs in how we conceptualize medicine as either driven and developed for the common good or specialized for the individual, Dickenson offers an important examination of contemporary medicine and a beautifully written account of what is at stake when the common good is overlooked. Hands down, she is one of the most insightful contributors to law and medicine discourse, and this book is a must-read for everyone concerned about the future of biotechnology.
Leslie Francis, University of Utah, co-author of The Patient as Victim and Vector: Bioethics and Infectious Disease:
Donna Dickenson's book is a seminal philosophical examination of the enthusiastic embrace of 'personalized medicine,' questioning easy assumptions about its benefits for patient care and for public health. Dickenson sounds powerful warnings about the extent to which personalized medicine risks confusion with individual self-interest and the devotion of biotechnology for private gain.
David Winickoff, University of California, Berkeley:
In this timely book, Dickenson levels trenchant criticism at the poster child of the twenty-first-century biomedical establishment: 'personalized medicine.' Analyzing an impressive array of practices in the new life sciences, she makes a persuasive argument that, as personalized medicine unfolds, market values and individualism are trumping the ideals of public health. This book comes at a critical moment. As we reappraise the social contract of health care, this book helps better direct research and development towards the common good.
Daniel Callahan, cofounder and president emeritus of The Hastings Center and author of The Roots of Bioethics: Health, Progress, Technology, Death:
Few words have as much ethical clout these days as that of 'choice,' a word that can be construed as the centrality of 'me.' Donna Dickenson's splendid book shows how deeply the 'me' has become embedded in medicine and abetted by the seemingly unchallengeable ethical concept of autonomy. What we have lost is the importance of 'we.' Using personalized medicine as her point of departure, she brilliantly works her way through a range of recent medical developments to show the damage the dominance of 'me' can bring. Her book can help restore the 'us' that has been diminished.
Sheldon Krimsky, Tufts University:
Donna Dickenson's book offers a compelling and overarching framework for interpreting new trends in biomedical science, such as gene biobanks, pharmacogenetics, and the banking of cord blood. It forces the reader to ask whether every new technological advance in medicine truly betters the field—and for whom.
